Blue Light Cystoscopy is poised to become the new standard of care in the diagnosis and treatment of Non-muscle invasive bladder cancer. This technology, used with the only FDA approved imaging agent for the procedure, is for enhanced visibility in the detection of Non-muscle invasive bladder cancer.

The Blue Light Cystoscopy uses KARL STORZ SAPHIRA™ equipment in combination with the pharmaceutical imaging agent Cysview® (hexaminolevulinate HCl) to cause cancerous tumors to glow a bright pink color in blue light. This enhanced visibility provides the following advantages:

• Increased detection of tumors ^[1]
• Enhanced tumor removal ^[2]
• Potentially improved risk categorization that informs treatment ^[3]

AUA/SUO Guidelines for Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer

^{1 Lotan Y BJU Int 2021 Vol. 127 Issue 1 Pages 108-113 DOI: 10.1111/bju.15166}

^{2 Hermann GG BJU Int 2011 Vol. 108 Issue 8 Pt 2 Pages E297-303 DOI: 10.1111/j.1464-410X.2011.10090.x}

^{3 Cahill EMCurr Urol 2022 Vol. 16 Issue 3 Pages 121-126 DOI: 10.1097/CU9.0000000000000142}